



### **Avila to Present at Lazard Capital Markets 8<sup>th</sup> Annual Healthcare Conference**

BEDFORD, MA - November 7, 2011 - Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that Katrine Bosley, Avila's CEO, is scheduled to present at the Lazard Capital Markets 8<sup>th</sup> Annual Healthcare Conference at 8:30 a.m. ET on Monday, November 15, 2011, at the Pierre Hotel, New York.

#### **About Avila Therapeutics™, Inc.**

Avila Therapeutics is a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best-in class outcomes. The company's product pipeline has been built using its proprietary Avilomics™ platform and is currently focused on cancer, viral infection and autoimmune disease. Avila's most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, is currently in Phase 1 clinical testing. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. For additional information, please visit <http://www.avilatx.com>.

Contact:  
Gina Nugent  
The Yates Network  
617-460-3579